Shore Capital has reiterated its buy rating on GSK with a fair value of 2,500p, citing undervaluation relative to growth potential. Recent positive developments include a US court ruling that may remove regulatory hurdles for GSK's vaccine franchises, and bullish internal views on the HIV injectable pipeline, particularly the Q6M treatment which could generate £10 billion annually by the early 2030s. Additionally, upcoming cancer drug launches could further boost GSK's outlook. Despite a recent 13% share price drop, Shore Capital sees this as an overreaction to fundamentals.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
